Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2008 by Illinois Retina Associates.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Alcon Laboratories
Information provided by:
Illinois Retina Associates
ClinicalTrials.gov Identifier:
NCT00690313
First received: May 30, 2008
Last updated: June 3, 2008
Last verified: May 2008

May 30, 2008
June 3, 2008
July 2008
June 2009   (final data collection date for primary outcome measure)
Timed study [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00690313 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections
To Compare the Efficacy of Topical Vigamox Eye Drops at Tid 3 Days Prior to Intravitreal Injection Versus Tid 1 Day Prior to Intravitreal Injection

Antibiotic eye drops are being used before and after intravitreal injections. Currently there is no study indicating the benefit of there usage or their dosage.

In this study we compare the efficacy of Vigamox eye drops (antibiotic)starting 3 days prior to the injection versus 1 day prior to intravitreal injection.

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Intravitreal Injection Patients
Drug: Vigamox
eye drops 3 times day either 1 or 3 days prior to intravitreal injection
  • Active Comparator: Arm 1
    Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection
    Intervention: Drug: Vigamox
  • Active Comparator: Arm 2
    Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection
    Intervention: Drug: Vigamox
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
40
September 2009
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient who need intravitreal injections patients who are willing to participate in the study

Exclusion Criteria:

  • Patients who are allergic to Vigamox or who have taken any eye drops within the past 3 weeks
Both
21 Years and older
No
Contact: Kourous A Rezaei, MD 708-596-8710 karezaei@yahoo.com
Contact: David J Baczewski 708-915-6808 davidb@illinoisretina.com
United States
 
NCT00690313
Vig508
Not Provided
Kourous Rezaei MD, Illinois Retina Associates SC
Illinois Retina Associates
Alcon Laboratories
Principal Investigator: Kourous A Rezaei, MD Illinois Retina Associates SC
Illinois Retina Associates
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP